Current and Future Management Options for T1D

Learning Objectives

• Recognize insulin replacement therapy treats the symptoms of T1D but does not eliminate the burden
• Highlight several investigational immunotherapies in Phase 2 and Phase 3 development have shown the ability to significantly preserve beta-cell function in recent-onset Stage 3 T1D
• Understand the future of T1D care looks to shift focus from insulin therapy to preserving beta cells 

Summary

So, what do we have at the moment for Type 1 diabetes management? It's definitely improving. Obviously, we have HbA1c. We have plasma glucose. But now we have CGM, and we have advanced insulin delivery. And all of these things are really positive and improving the lives of our patients. But there's still the burden and the fear of hypoglycemia and the burden of insulin management and adjustment.

In summary, insulin replacement treats the symptoms, but it doesn't change the course of the disease. We've got several investigation immunotherapies in Phase 2 and Phase 3, which can change the cause of the diseases. So, I think the future of type 1 diabetes looks to shift the focus from just waiting until you give insulin to preserving beta cells. 

MAT-GLB-2505835 - 1.0 - 10/2025